A joint statement issued by Massachusetts Gov. Charlie Baker, chair of the National Governors Association's (NGA) Health and Human Services Committee, along with New Hampshire Gov. Maggie Hassan, the committee's vice chair, and Patrice Harris, chair-elect of the American Medical Association (AMA), placed another thorn in the side of the FDA a day after Titan Pharmaceuticals Inc. and partner Braeburn Pharmaceuticals Inc. disclosed that the agency extended by three months the PDUFA date for Probuphine, designed for the maintenance treatment of opioid addiction.